Finance

Lists
Why is MRK down 2.31%?
Dive Deeper
MRK:NYSE
Merck & Co Inc
$147.43
-2.31%
(-3.48) 1D
Sep 23, 2:45:49 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRK...
Open
$151.32
High
$152.01
Low
$146.89
Mkt. cap
363.74B
Avg. vol.
11.06M
Volume
4.58M
Dividend
2.31%
Quarterly dividend
$0.85
Ex-dividend date
Sep 15, 2026
P/E ratio
117.75
52-wk high
$156.92
52-wk low
$77.58
EPS
$1.25
Beta
0.22
Shares outstanding
2.47B
No. of employees
74K
Open
$151.32
High
$152.01
Low
$146.89
Mkt. cap
363.74B
Avg. vol.
11.06M
Volume
4.58M
Dividend
2.31%
Quarterly dividend
$0.85
Ex-dividend date
Sep 15, 2026
P/E ratio
117.75
52-wk high
$156.92
52-wk low
$77.58
EPS
$1.25
Beta
0.22
Shares outstanding
2.47B
No. of employees
74K
News stories
From web sources and news partners
Profile
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
About Merck & Co Inc
CEORobert M Davis
Employees74K
FoundedJan 1, 1891
Headquarters-
SectorPharmaceutical industry
Websitemerck.com
Analyst ratings
Based on 20 analysts giving stock ratings to MRK in the past 3 months
Buy
Buy
14
Hold
6
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for MRK in the last 3 months.
Highest
Current $147.43
$180.00 (+22.09%)
Average
$160.08 (+8.58%)
Lowest
$105.00 (-28.78%)
Analyst
Recommendation
Action
Price target
Projected
Date
Louise Chen
Scotiabank
Buy
Maintained
$155.00
+5.1%
09/23/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$166.00
+12.6%
09/23/2026
Geoff Meacham
Citi
Hold
Maintained
$125.00
-15.2%
09/23/2026
Steve Scala
TD Cowen
Hold
Maintained
$155.00
+5.1%
09/22/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$179.00
+21.4%
09/20/2026
Trung Huynh
RBC Capital
Hold
Maintained
$150.00
+1.7%
09/14/2026
Nico Chen
DBS
Buy
Maintained
$180.00
+22.1%
09/11/2026
Rajesh Kumar
HSBC
Buy
Maintained
$172.00
+16.7%
09/10/2026
Daina Graybosch
Leerink Partners
Buy
Reiterated
$161.00
+9.2%
09/10/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$170.00
+15.3%
09/08/2026
Emily Field
Barclays
Hold
Reiterated
€150.00
+1.7%
09/07/2026
Courtney Breen
Bernstein
Hold
Maintained
$105.00
-28.8%
09/07/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$170.00
+15.3%
09/04/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
$170.00
+15.3%
08/24/2026
Alexandria Hammond
Wolfe Research
Buy
Maintained
$180.00
+22.1%
08/25/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
$170.00
+15.3%
08/20/2026
Michael Yee
UBS
Buy
Maintained
$175.00
+18.7%
08/20/2026
Asad Haider
Goldman Sachs
Buy
Maintained
$160.00
+8.5%
08/20/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
08/19/2026
Luisa Hector
Berenberg Bank
Hold
Maintained
$127.00
-13.9%
08/05/2026
Unknown Analyst
Jefferies
Buy
Maintained
$138.00
-6.4%
05/19/2026
Unknown Analyst
Argus Research
Buy
Reiterated
$130.00
-11.8%
05/08/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Natalya Davies
Rothschild & Co Redburn
Buy
Maintained
$179.00
+21.4%
04/17/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
$120.00
-18.6%
03/29/2026
James Shin
Deutsche Bank
Buy
Upgraded
$150.00
+1.7%
02/13/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.13 / -$0.26
+49.43%beat
Revenue / Est. (USD)
16.61B / 16.37B
+1.46%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
17.28B
16.40B
16.29B
16.61B
Cost of goods sold
3.74B
4.30B
3.88B
4.13B
Cost of revenue
3.74B
4.30B
3.88B
4.13B
Research and development expenses
4.00B
4.00B
3.56B
9.74B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.48B
2.73B
2.57B
2.78B
Operating expense
6.48B
6.73B
6.12B
12.52B
Total operating expenses
10.23B
11.02B
10.00B
16.65B
Operating income
7.05B
5.38B
6.29B
-40.00M
Other non operating income
-
41.00M
42.00M
59.00M
EBT including unusual items
6.74B
3.42B
-3.53B
-683.00M
EBT excluding unusual items
6.76B
4.98B
5.85B
-508.00M
Income tax expense
958.00M
458.00M
709.00M
654.00M
Effective tax rate
14.20%
13.39%
-20.06%
-95.75%
Other operating expenses
-
-
-
-
Net income
5.78B
2.96B
-4.24B
-1.34B
Net profit margin
33.49%
18.07%
-26.03%
-8.04%
Earnings per share
2.58
2.04
-1.28
-0.13
Interest and investment income
96.00M
69.00M
35.00M
35.00M
Interest expense
-327.00M
-411.00M
-479.00M
-525.00M
Net interest expenses
-231.00M
-342.00M
-444.00M
-490.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
8.15B
6.79B
7.69B
1.43B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps